Association for Accessible Medicines

11/10/2025

Generic medicines give America's patients the confidence to thrive! Last year, comprised 90% of all prescriptions filled, but only 12% of prescription spending. In sharp contrast, brand drugs supported patients less often— making up only 10% of prescriptions filled but adding up to 88% of the total drug spend. Learn more about what makes generic medicines unique in AAM’s : https://accessiblemeds.org/resources/blog/2025-savings-report

11/06/2025

In 2024, & saved America’s patients and the U.S. healthcare system $467 billion—and $3.4 trillion in the past 10 years. Learn more, including what can be done to help safeguard this important industry: https://accessiblemeds.org/resources/blog/2025-savings-report

11/04/2025

10/28/2025

Read our Day 1 Recap: https://accessiblemeds.org/resources/blog/grxbiosims-2025-day-1-recap/

10/27/2025

2025 is underway in Rockville, MD—with our afternoon learning tracks sessions now getting started!

We are thrilled to welcome around 500 leaders in the generic and biosimilar medicines industry; and looking forward to 3 days of knowledge sharing, networking and fun! 

10/24/2025

⏰ Just a few days away! 2025 kicks off October 27–29 in Rockville, MD. Join the brightest minds in generics and biosimilars for three days of insights, strategy, and connection. This is the leading scientific and regulatory event shaping the future of accessible medicines — and you won’t want to miss it.

Register now! https://grxbiosims.org

10/23/2025

In the past decade, and medicines have saved the U.S. healthcare system $3.4 trillion. Still, threats to the sustainability of this essential industry remain. Policymakers must ACT NOW to streamline FDA processes, curb patent abuse, stop PBMs and Medicare policies from denying patient access, and rollback harmful federal policies – including IRA price controls – to safeguard the livelihood of America’s patients. Learn more in the : https://accessiblemeds.org/resources/blog/2025-savings-report

10/22/2025

Don’t miss this vital conversation on the future of affordable medicines. Experts dive into drug shortages, patent strategies & policy shifts shaping & . Get the insights you need to stay ahead. Register today: https://grxbiosims.org

10/21/2025

Over the next decade, 118 biologics are expected to lose patent exclusivity, presenting a $234 billion opportunity for biosimilars in the U.S. But of these 118 biologics, only 12 molecules currently have biosimilars in development. Closing this biosimilar void requires coordinated action across an entire ecosystem of stakeholders – manufacturers, providers, payers, and policymakers. Learn more on what needs to change: https://accessiblemeds.org/resources/blog/2025-savings-report

10/20/2025

🔥 Don’t miss the Fireside Chat at 2025, Oct 27–29 in Rockville, MD! Hear from Dr. Marty Makary and AAM CEO John Murphy III as they explore the future of generics, biosimilars, and healthcare innovation.
🎟️ Be part of the conversation! Register today: https://grxbiosims.org/